^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

HBM1047

i
Other names: HBM1047
Associations
Trials
Company:
Harbour BioMed
Drug class:
CD200R1 antagonist
Associations
Trials
2years
HBM1047, a novel fully human anti-CD200R1 antagonist antibody with potent anti-tumor efficacy in preclinical model (SITC 2022)
In addition, HBM1047 had a favorable PK profile in mice and exhibited good developability properties. Conclusions In conclusion, HBM1047 represents a novel fully human anti-CD200R1 antagonistic antibody with promising therapeutic potential for the treatment of cancer.
Preclinical • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • CD200 (CD200 Molecule)
|
CD200 expression
|
HBM1047